6 results about "Methylphenidate" patented technology

This invention discloses a method for resolving isomers of methylfenacin ester, comprising: firstly, dissolving methylfenacin ester in a first solvent and adding L-tartaric acid, dissolving until clear; then adjusting the system temperature to 40℃-53℃ and adding L-tartaric acid seed crystals of the target isomer; subsequently, cooling the system to 20℃-30℃, filtering the precipitated product, and obtaining the L-tartaric acid seed crystals of the target isomer as the filter cake; dissociating the L-tartaric acid seed crystals of the target isomer using an alkaline resin, collecting the filtrate, and drying the filtrate to obtain the target isomer of methylfenacin ester. This invention achieves the resolution of isomers of methylfenacin ester by using L-tartaric acid, and through optimization of conditions, achieves a yield of not less than 74.1% and an ee of 91.1% for the target isomer of methylfenacin ester. The resolution method provided by this invention is simple to operate, easy to control, suitable for large-scale production, and meets industrial needs.

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

This invention relates to a hybridoma cell line that secretes a monoclonal antibody against methylphenidate and its application. The hybridoma cell line was deposited on October 31, 2024, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 46223, located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, and is classified as a monoclonal cell line. The monoclonal antibody against methylphenidate secreted by this hybridoma cell line exhibits good detection sensitivity (IC50) for methylphenidate. 50 With a value of 1.02 ng / mL, it can be used for the detection of methylphenidate residues.

The application discloses application of methylphenidate in preparation of a post-traumatic stress disorder (PTSD) psychotherapy enhancer. The methylphenidate is used in the introduction period of PTSD psychotherapy, and can improve the treatment effect of core symptoms of PTSD, including intrusive symptoms, avoidance symptoms, high vigilance symptoms, negative thinking and emotion. The application uses single methylphenidate to disturb patients into an unstable state, adjusts a time window for reconsolidation of trauma memory, and strengthens the decline of trauma memory and the update of healing memory in the time window. Furthermore, compared with daily medication, single medication has clinical significance of reducing the psychological burden and economic burden of patients on drug use. Therefore, the application uses single methylphenidate in the introduction period of PTSD psychotherapy.

Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.